Techno Drugs introduces region’s first single-rod contraceptive implant
Techno Drugs Ltd, one of Bangladesh's leading pharmaceutical companies, has achieved a historic milestone with the launch of its first-ever single rod contraceptive implant manufacturing. With this breakthrough, the company becomes the only manufacturer in South Asia and the second in the world to produce single rod implants, replacing the previously used double rod version.
Techno Drugs began producing contraceptive implants in 2019 after establishing its Contraceptive Manufacturing Facility — the only such plant in Bangladesh and one of just five worldwide. Since then, research and development on single rod implants has been led by the company's Managing Director, Shah Jalal Uddin Ahmed, a renowned pharmacist.
The new facility includes a dedicated section for producing single rod implants under the brand name "ETO Plant". It is designed to provide safe, effective, and long-term contraceptive solutions, strengthening Bangladesh's position in global reproductive healthcare manufacturing and reducing dependency on imports.
Keep updated, follow The Business Standard's Google news channel
Arefeen Raafi Ahmed, Executive Director of Techno Drugs Ltd, said: "This is not just a milestone for Techno Drugs, but for the entire region. By establishing South Asia's first and the world's second dedicated single rod implant plant, we are redefining accessibility, affordability, and innovation in contraceptive healthcare."
Founded in 1996, Techno Drugs has consistently advanced pharmaceutical innovation, from oncology to hormonal medicines. The company pioneered the local manufacture of oncology drugs in 2010 and established the largest contraceptive injectable manufacturing plant in South East Asia in 2018. Its oncology facility has been operational for 15 years, designed in line with international Good Manufacturing Practice (GMP) standards.
With ISO 9001:2015 certification, strict GMP compliance, and a strong export presence across Asia and Africa, Techno Drugs continues to expand access to affordable, high-quality oncology and reproductive healthcare solutions, positioning itself as a rising global pharmaceutical leader.
